Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on June 10, 2024. The company is an emerging growth company incorporated in Nevada, with its principal executive offices in Boca Raton, Florida. The report primarily addresses a compensatory arrangement for the Chief Executive Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity grant event.
Material Changes and Events
- Executive Compensation Grant: On June 10, 2024, the Board of Directors approved an incentive stock option for Ramond J. Tesi, the Company's Chief Executive Officer.
- Option Details: The option covers 37,882 shares of common stock with an exercise price of $8.72 per share.
- Vesting and Term: The option vested and became exercisable immediately upon the grant date. It expires on June 9, 2034.
- Plan Authority: The grant was issued under the Company's 2021 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, operational outlook, or specific risk factors. The only contingency noted is that the summary of the option agreement is qualified in its entirety by reference to the full agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the total number of shares reserved under the 2021 Stock Incentive Plan to assess remaining capacity for future grants.
- Review the full Incentive Stock Option Agreement (Exhibit 10.1) for specific performance conditions or clawback provisions not detailed in the summary.
- Confirm the current market price of INMB stock relative to the $8.72 exercise price to evaluate the immediate intrinsic value of the grant.
- Check subsequent filings for any dilution impact on existing shareholders resulting from this grant.